Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Trophic factor for dopamine neurons.
Showing 10 out of 94 products:
Human Polyclonal CDNF Primary Antibody for IHC, ELISA - ABIN1002133
Petrova, Raibekas, Pevsner, Vigo, Anafi, Moore, Peaire, Shridhar, Smith, Kelly, Durocher, Commissiong: MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. in Journal of molecular neuroscience : MN 2003
Show all 2 Pubmed References
Human Polyclonal CDNF Primary Antibody for IHC, ELISA - ABIN1002134
Lindholm, Voutilainen, Laurén, Peränen, Leppänen, Andressoo, Lindahl, Janhunen, Kalkkinen, Timmusk, Tuominen, Saarma: Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. in Nature 2007
Show all 2 Pubmed References
Human Polyclonal CDNF Primary Antibody for IF (p), IHC (p) - ABIN1387519
Zhao, Cheng, Du, Hou, Liu, Cui, Nie: Transplantation of Cerebral Dopamine Neurotrophic Factor Transducted BMSCs in Contusion Spinal Cord Injury of Rats: Promotion of Nerve Regeneration by Alleviating Neuroinflammation. in Molecular neurobiology 2014
Human Polyclonal CDNF Primary Antibody for IHC, ELISA - ABIN1030330
Garea-Rodríguez, Eesmaa, Lindholm, Schlumbohm, König, Meller, Krieglstein, Helms, Saarma, Fuchs: Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease. in PLoS ONE 2016
In various animal models of Parkinson Disease, CDNF is efficient in protecting and repairing dopaminergic neurons, and it inhibits endoplasmic reticulum stress, euroinflammation, and apoptosis.
The results showed that AAV8-CDNF administration significantly improved the motor function and increased the tyrosine hydroxylase (TH (show TH Antibodies)) levels in Parkinson's disease rats with mild lesions (2 weeks post lesion), but it had limited therapeutic effects in rats with severe lesions (5 weeks post lesion).
Results suggest that CDNF treatment selectively enhances long-term memory consolidation
showed that CDNF was able to protect dopaminergic neurons against injury caused by alpha-synuclein oligomers. This advises its use against physiological damages caused by alpha-synuclein oligomers
Expression of CDNF in the substantia nigra has an anti-inflammatory effect on experimental Parkinson's disease.
Although no CDNF mutations are found in early-onset Parkinson's disease patient samples, a trend towards increased risk for Parkinson's in carriers of the C allele of rs7094179 single nucleotide polymorphism (SNP) is found.
expressed in several tissues; might be beneficial for the treatment of Parkinson's disease
structures of MANF (show MANF Antibodies) and CDNF were solved; structure explains why MANF (show MANF Antibodies) and CDNF are bifunctional; neurotrophic activity may reside in the N-terminal domain and ER stress response in the C-terminal domain
Study suggests that there is no association between variants in the CDNF gene and cocaine dependence.
secretion of mouse MANF (show MANF Antibodies) and mouse CDNF is fundamentally regulated in the same manner, the variation of four C-terminal amino acids in the MANF (show MANF Antibodies) and CDNF among species might influence their intracellular functions.
This study demonstrated that decrease in mRNA level of CDNF in brain in microgravity.
CDNF (Armetl1) is expressed in several tissues, including the mouse embryonic and postnatal brain
Trophic factor for dopamine neurons. Prevents the 6- hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons. When administered after 6-OHDA-lesioning, restores the dopaminergic function and prevents the degeneration of dopaminergic neurons in substantia nigra.
ARMET-like protein 1
, arginine-rich, mutated in early stage tumors-like 1
, conserved dopamine neurotrophic factor
, arginine-rich protein mutated in early stage tumors-like 1